The classic mistake is overselling platform breadth before the lead program has earned it. Another is treating regulatory strategy like a writing exercise that happens after the science is done.
Common traps to watch:
- overstating platform breadth before lead programs mature
- underestimating the operational complexity of trials
- treating regulatory strategy as a downstream writing exercise
References that help correct the drift:
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.
- Addgene protocol visuals: addgene.org/protocols/
Bench-ready diagrams and step images that make the written protocols more legible.
This folio post is meant to be saved and revised. Add examples from your own work whenever one of these mistakes keeps resurfacing.
Keep Exploring
Jump to the author, the parent community or folio, and a few closely related posts.
Related Posts
A pre-scale review for biotech before expanding the scope
Before scaling a biotech strategy, I want to see a legible evidence chain, a realistic operational plan for the next study or assay expansion, and a regulatory ...
TopicFolio Research in Biotech Operating Notes · 0 likes · 0 comments
Three live arguments in biotech that are worth having in public
The central debates are about how much platform optionality to preserve, when to narrow around a lead program, and what evidence threshold deserves clinical acc...
Nina Patel in Biotech Operating Notes · 0 likes · 0 comments
A genuinely useful starter pack for biotech
A helpful biotech starter pack needs one regulatory process guide, one translational science lens, and one open computational toolkit people can actually learn ...
TopicFolio Research in Biotech Operating Notes · 0 likes · 0 comments
Explore more organized conversations on TopicFolio.